Founded in 1956, the mission for Zhejiang HISUN Pharmaceuticals Co., Ltd. (stock code 600267) hereinafter called "HISUN") is one of "To be persistent in pharmaceutical innovation for humans' well-being". The company's vision is to become "a widely respected global pharmaceutical provider".It focuses on the integration of pharmaceutical research and development (R&D) with production resources in order to provide its global customers with outstanding products and services.To date, over 40 of the company's products have passed certification by the FDA (U.S.),EDQM (EU) ,TGA (Australia) ,KFDA(Korea), etc.,and are sold to more than 30 countries worldwide.
Over the years, HISUN has received numerous commendations and accolades. For example, in 2009 the company received the "May 1st Labor Award". The company's name in Chinese and English (HISUN) and its logo were recognized as "Famous Brands in China". The company was also selected to participate in "China's Genome Project for 10,000 Micro-organisms" and "National Technical Innovation Alliance for Commercialization of Major Pharmaceuticals". As a result of its successful completion of the Central Government's assignment with respect to the production of "anti-H1N1 pharmaceutical intermediate agents", the company was commended by the Zhejiang Provincial Government.
In 2010, Hisun was selected as the "Top 10 Enterprises " of ZheJiang Medicine Industry, and honored as the "Top 10 Industrial Enterprises of Optimum Product Lines in China ", and at the same time, Hisun awarded the "Gold Bee Prize of Growing Enterprise". At the same year, Hisun achived sales revenue of RMB 4.5 billion, total profit of RMB 450 million, which were 14.4% and 28.2% respectively higher than the previous year.